TIMOTHY C BARABE
CIK 1237409 · Chief Financial Officer · last filed 2026-07-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.64M
Companies
7
Total Filings
270
Lifetime Open-Market Net
-$3.29M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HTFL | Director | 188,231 | $29.66 | $5.58M | $0 | 6 | 2026-07-24 |
| RNAC | Director | 56,966 | $8.79 | $500.7K | $301.0K | 6 | 2026-01-06 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 250,013 | $0.88 | $220.3K | $273.7K | 20 | 2023-01-04 |
| VEEV | Director | 6,643 | $234.85 | $1.56M | -$1.35M | 39 | 2021-06-23 |
| Acer Therapeutics Inc. (OPXAW) Delisted | Director | 20,719 | — | — | $3.3K | 11 | 2016-11-22 |
| AFFYMETRIX INC (AFFX) Delisted | Chief Financial Officer | 166,378 | — | — | $337.8K | 21 | 2013-03-20 |
| HUMAN GENOME SCIENCES INC (HGSI) Delisted | Chief Financial Officer | 49,570 | — | — | -$2.85M | 16 | 2010-02-22 |
Recent Filings · Page 4 of 27
270 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-22 | VEEV | Exer (M) | +347 | $0 | EDGAR |
| 2020-04-09 | VEEV | Sell (S) | −347 | -$54.1K | EDGAR |
| 2020-03-23 | VEEV | Exer (M) | +346 | $0 | EDGAR |
| 2020-03-19 | Cartesian Therapeutics, Inc. (SELB) Delisted | Buy (P) | +5,000 | $10.0K | EDGAR |
| 2020-01-16 | — | Mixed | −146,897 | -$2.94M | |
| 2019-12-26 | Cartesian Therapeutics, Inc. (SELB) Delisted | Grant (A) | +65,681 | $95.9K | EDGAR |
| 2019-12-20 | VEEV | Exer (M) | +347 | $0 | EDGAR |
| 2019-09-23 | VEEV | Exer (M) | +347 | $0 | EDGAR |
| 2019-08-15 | Cartesian Therapeutics, Inc. (SELB) Delisted | Buy (P) | +10,000 | $17.2K | EDGAR |
| 2019-06-21 | VEEV | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.